viewArix Bioscience PLC

Arix Bioscience boost after Harpoon NASDAQ float

The fair value of the company's investment in Harpoon has grown by £6.2mln

dna strands
This is the fourth Arix portfolio company in three years to find its way onto the public markets

Healthcare investment company Arix Bioscience Plc (LON:ARIX) said a fourth portfolio company is listing on the stock market, increasing the valuation of its shareholding.

Harpoon Therapeutics, which is developing T-cell immunotherapies for cancer, is raising £58.4mln from the NASDAQ float.

READ: Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

Arix has followed its money by ploughing £4.6mln into the IPO. This takes its stake to 12.1%, which is worth £31.3mln, which includes a boost to the fair value of the original holding of £6.2mln.

“Coupled with its scientific expertise and strong management team, we believe Harpoon is well-positioned to play a significant role in immuno-oncology,” said chief investment officer Joe Anderson.

“As early investors in Harpoon, we are excited to see the potential of the company continue to grow.”

Quick facts: Arix Bioscience PLC

Price: 78.5 GBX

Market: LSE
Market Cap: £106.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Arix Bioscience PLC: Proactive One2One Virtual Event

Arix Bioscience PLC's (LON:ARIX) Jonathan Tobin pitches the company to investors at the Proactive One2One Virtual Event. Arix is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

on 14/6/20

2 min read